HA
Therapeutic Areas
Immuneering Pipeline
| Drug | Indication | Phase |
|---|---|---|
| IMM-1-104 (implied lead) | Advanced solid tumors with MAPK pathway mutations (e.g., KRAS, NRAS, BRAF) | Phase 1/2a |
| Preclinical Programs | MAPK-driven cancers | Preclinical |
Leadership Team at Immuneering
BZ
Ben Zeskind
Co-Founder, President, Chief Executive Officer, Director
MB
Michael Bookman
Chief Legal Officer, Secretary
H“
Harold “E.B.” Brakewood
Chief Business Officer
BH
Brett Hall
Chief Scientific Officer
TS
Tom Schall
Board Chair
BC
Bob Carpenter
Co-founder, Chair Emeritus, Board Member
PF
Peter Feinberg
Board Member
CA
Christian Alaia
Senior Director, Financial Planning & Analysis
NA
Naseem Alkaabi
Senior Research Associate
DA
Damaris Arcila
Senior Accountant